Spyre Therapeutics
SYRE
SYRE
135 hedge funds and large institutions have $1.08B invested in Spyre Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.9% more ownership
Funds ownership: 105.56% → 106.45% (+0.9%)
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
135
Holding in Top 10
1
Calls
$1.6M
Puts
$838K
Top Buyers
| 1 | +$18.4M | |
| 2 | +$13.6M | |
| 3 | +$6.84M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$6.26M |
| 5 |
JP Morgan Chase
New York
|
+$3.83M |
Top Sellers
| 1 | -$9.13M | |
| 2 | -$6.76M | |
| 3 | -$5.64M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5.59M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.19M |
